Fig. 4From: Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case reportDetails of the second cycle of ipilimumab/nivolumab combination therapy including myocarditis as immune-related adverse events managementBack to article page